IL-27 is a protective cytokine during congenital infection
INSTITUTION
University of Pennsylvania, PA
PRINCIPAL INVESTIGATOR
Jurado, Kellie Ann (Contact)
FUNDING
$556K
YEAR
2024
MOONBASE SCORE
Still being scored
LOADING MOONBASE SCORE
Abstract
Cytokines govern key cellular processes of pregnancy with both pro- and anti-inflammatory activities. To prevent immune dysregulation at the maternal-fetal interface, cytokines are thought to dictate these seemingly contradictory immune responses through meticulous immune regulation. Yet, there is a gap in knowledge regarding the mechanistic roles of many cytokines in the context of pregnancy, including the versatile cytokine Interleukin 27 (IL-27). Our proposal will address this gap in knowledge, as we have recently established that the IL-27 signaling circuit is active at the maternal-fetal interface and discovered that IL-27 is a protective cytokine during congenital infection. IL-27 serves as a potent regulatory of inflammation, where it can be pro- or anti- inflammatory dependent upon cellular context. Although initially recognized for its proinflammatory activities in promoting immunity, IL-27 was later acknowledged for its profound ability to serve as an anti-inflammatory cytokine during various infections where IL-27 has been found to act on various T subsets cells to limit inflammation during infection. Moreover, IL-27 can directly influence viral infection through induction of antiviral genes in IL-27 responsive cells. Based on literature and our extensive preliminary data, we hypothesize that IL- 27 is both an immunoregulatory and antiviral cytokine during pregnancy. This proposal describes targeted objectives to define the mechanistic features of IL-27 signaling at the maternal-fetal interface that underlie its protective capacity during congenital infection. In Aim 1 we will focus our investigations on defining the immune regulatory functions of IL-27 at the maternal-fetal interface. We will uncover the cellular targets and impacts of IL-27 signaling in dictating activation state of localized T cells. In Aim 2 we will focus our studies on the antiviral functions of IL-27 in the placenta. We will evaluate the transcriptional dynamics of IL-27 signaling and antiviral capacity of IL-27 signaling in mouse and human placental trophoblast organoids. Altogether, outcomes from this proposal will embody new fundamental insights into regulatory cytokine communication at the maternal-fetal interface. Specifically, this proposal will define the mechanisms underlying IL-27 protective immunity during congenital infection, which could ultimately be leveraged to improve maternal and neonatal outcomes.
Are you the primary organization running this research?
The two tools below are built for the principal investigator & host institution behind this project.